Strategies in Today’s Market for Pricing and Reimbursement Models
July 14th 2025A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models that require strong value propositions, strategic planning, and significant upfront investment in data and stakeholder alignment.
Challenges for Bringing Orphan Drugs to Market
July 9th 2025Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests strategies that can be used to address evidence gaps, enable market access, and support long-term patient benefit.
Harmonizing the Payer Perspective with Real-World Evidence
July 7th 2025Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and AI-driven insights to address skepticism and support broader reimbursement and access strategies as payers balance real-world evidence with head-to-head clinical trials in their decision-making.
Effective Real-World Evidence for Adding Value to a Clinical Trial
June 30th 2025In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical trials, key opinion leaders emphasize finding cost-effective approaches, considering diverse patient populations, and using AI to pinpoint which patients will benefit most from treatment.
Navigating Regulatory Barriers within Market Access
June 25th 2025A panel of industry leaders emphasize the importance of early engagement with payers, real-world evidence, and value-based endpoints to ensure successful access, pricing, and long-term market viability—especially in a more complex, globally integrated reimbursement landscape.
Industry Voices on Current Pricing and Reimbursement Models
June 23rd 2025Leading stakeholders in the industry react to how evolving US policies, payer demands, and vertical integration are reshaping market access strategy, stressing the importance of early planning and the urgency of ensuring that innovative therapies are available and affordable for patients.
Herspiegel Consulting Dives Into the Value Narrative
May 6th 2025Kapil Raina, MD, Principal of Market Access at Herspiegel Consulting, talks about disconnects in the industry, how patients have easier access to healthcare information, and the exciting future of pharmaceutical manufacturing and patient care.
Industry Trends, Policy Challenges, and Educational Initiatives with Joseph Panetta
October 1st 2024Joseph Panetta, President and CEO of Biocom California, shares his insights on biotech industry trends, policy challenges, and educational initiatives, drawing from over 25 years of leadership in California’s thriving life sciences sector.
Max Colao Shares How OncoVerity is Pioneering Oncology Solutions
September 24th 2024Max Colao, CEO of OncoVerity, discusses his extensive experience in the biotech industry and shares how his company is harnessing computational biology and machine learning to develop personalized cancer treatments that aim to reshape the future of oncology care.
Elyse Blazevich on Driving Innovation in Colorado's Thriving Life Sciences Ecosystem
September 17th 2024Elyse Blazevich discusses the Colorado Bioscience Association’s efforts to support the state’s life sciences sector by fostering partnerships, advocating for industry growth, and building a diverse talent pipeline.
Deep Dive into the Use of Real-World Registry Data as External Control Arms
July 31st 2023While clinical registries are a valued source of longitudinal, real-world data, registries also provide expanded options for research and advancing randomized clinical trials. Understanding when and how to use registries in these use cases is quite nuanced and mandates a targeted approach and innovative expertise. In this video, we dive deep into the expanded use of registries as external control arms in clinical trials.
Digital Medicine and Pharma: The Partnerships Bringing Together Molecule and Software
November 29th 2022Pharmaceutical Executive, in collaboration with Biofourmis, organized a roundtable of experts from various groups to discuss how digital medicine and pharmaceuticals are changing the trajectory of what drug development and clinical care look like together, with an emphasis on partnerships within digital health.
The Importance of Imaging and Centralized Review in Clinical Trials
August 16th 2022Imaging is an integral part of many clinical studies, particularly in the fields of oncology and ophthalmology. Learn why imaging and centralized review are essential for clinical trials, how to address challenges that arise in these studies, and the advantages of partnering with MERIT in this video.
Understanding Real-World Evidence and Data and Their Use
May 6th 2022As life science organizations continue to leverage both real world data [RWD] and real-world evidence [RWE] in the product approval landscape, a more nuanced understanding of both RWD and RWE is needed. Given the expansive types of data available now, understanding which data set is needed and how it should be analyzed is decidedly valuable. Our expert provides basic tenets for consideration